StockNews.AISignal intelligence
AngioDynamics, Inc. · NASDAQ · Healthcare
Browse public ANGO signals with their source context and measured market impact. Open any signal for its permanent analysis page.
AngioDynamics reported better-than-expected quarterly earnings, showing improved financial performance. The company posted losses of 10 cents per share, beating estimates by 2 cents. Quarterly sales reached $75.711 million, exceeding the consensus of $72.725 million. AngioDynamics raised its FY26 adjusted EPS and sales guidance, indicating positive future outlook.
View signal analysisANGO to report Q1 earnings on October 2. Projected loss of 12 cents per share indicates potential ongoing challenges. Quarterly revenue expected to rise to $72.69 million, showing growth. Analysts maintain Buy ratings, projecting targets from $16 to $17. Shares rose 4% to $11.17 prior to earnings release.
View signal analysisANGO's Q4 loss was 3 cents per share, beating expectations. Sales reached $80.2 million, exceeding consensus estimates by 8.7%. Med Tech sales rose 22% year-over-year, primarily driven by Auryon. 2026 revenue guidance is $305-$310 million, slightly exceeding consensus. Stock increased 5.3% to $10.14 following positive earnings report.
View signal analysisANGO's Q3 2025 adjusted EPS was 3 cents, surpassing a 13-cent loss estimate. Sales reached $72 million, beating expectations and up 9.2% year-over-year. Gross margin rose to 54%, a 290 basis point improvement from last year. Fiscal 2025 sales forecast is $285-$288 million, ahead of prior estimates. Stock surged 10.09% to $10.63 following the earnings report.
View signal analysisAngioDynamics reported a Q1 loss of 11 cents, better than expected. Quarterly sales were $67.491 million, slightly under expectations. ANGO shares dropped 15.6% to $6.45 following earnings announcement. U.S. stocks generally fell, with the Dow down around 300 points.
View signal analysisAngioDynamics Inc reported Q4 2024 EPS loss of $0.05 vs. consensus loss of $0.16. Q4 sales totaled $70.98 million, beating analyst consensus of $70.89 million. Guidance for FY 2025 expects net sales of $282 million-$288 million. Med Tech segment net sales were $29.3 million, up 11.3% year over year. AngioDynamics announced a stock repurchase program of up to $15.0 million.
View signal analysis